Radha Gopalan, MD
Advanced Heart Failure and Transplant Cardiology · Phoenix, AZNPI 1043280787
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,098 of the $32,052 with a category attached, or 72.1%. Bayer accounts for 74.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $18,682 and has fallen 98.3% since, to $317 in 2025.
Across 151 payments — averaging $212.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$24K
- Abbott$4K
- Novartis$3K
- Impulse Dynamics (USA) Inc.$417
- Boehringer Ingelheim$164
- La Jolla Pharmaceutical Company$164
- plus $1K from 19 others
Across 64 payments — averaging $2837.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$66K
- American Regent$31K
- Impulse Dynamics (USA) Inc.$31K
- Nuwellis, Inc.$25K
- Carmat$22K
- United Therapeutics Corporation$6K
What the payments were for
- Consulting fees$2,1807%
- Speaking & faculty fees$23,09872%
- Food & beverage$6,72621%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 19 | $23,848 |
| Abbott | 47 | $3,724 |
| Novartis | 39 | $2,690 |
| Impulse Dynamics (USA) Inc. | 9 | $417 |
| Boehringer Ingelheim | 3 | $164 |
| La Jolla Pharmaceutical Company | 2 | $164 |
| Abiomed | 4 | $162 |
| United Therapeutics Corporation | 2 | $118 |
| Boston Scientific | 1 | $105 |
| Nuwellis, Inc. | 2 | $100 |
| Cardiac Dimensions, Inc. | 1 | $90 |
| Medtronic | 3 | $59 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $58 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Daxor Corporation | 2 | $41 |
| Livanova USA, Inc. | 1 | $41 |
| Cvrx, Inc. | 1 | $35 |
| Atricure, Inc. | 1 | $34 |
| AstraZeneca | 2 | $34 |
| Kestra Medical Technology Services, Inc. | 1 | $30 |
| Bridgebio Pharma, Inc. | 1 | $25 |
| Merck | 1 | $21 |
| Haemonetics Corporation | 1 | $19 |
| Pfizer | 1 | $13 |
| Cardiva Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$23,781
- ENTRESTO$1,980
- CardioMEMS HF System$1,054
- CARDIOMEMS$617
- HeartMate 3 Left Ventricular Dev$260
- OPTIMIZER SMART SYSTEM$259
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$228
- AMPLATZER$174
- EnSite Precision Cardiac Mapping System$147
- MitraClip System$134
- Quadra Assura CRT Defibrillator$123
- JARDIANCE$113
- GENERAL TACHY$105
How this compares
Too few advanced heart failure and transplant cardiology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 21 | $32,542 |
| JardianceEmpagliflozin | 13 | $16,116 |
| Eplerenone | 19 | $739 |
| Torsemide | 19 | $273 |
| Metoprolol Succinate | 23 | $226 |
| Carvedilol | 27 | $181 |
| Spironolactone | 27 | $163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $2,690 | $32,54221 claims |
| Boehringer IngelheimJardiance | $164 | $16,11613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Phoenix
- David SteidleyPhoenix$57K
- Andrew BosharaPhoenix$14K
- Suresh YerraPhoenix$1K
- Anantharam KalyaPhoenix$1K
- Anita PhancaoTucson$31K
- Geoffrey JaoScottsdale$21K
- Carl TongTucson$346
- Wassim AssaadScottsdale$313
- Katie MurphyScottsdale$305
- Sharon PowellTucson$289
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.